RESUMO
The effects of recombinant human erythropoietin (rHuEPO) on survival and blood pressure in hypovolemic hemorrhagic shock in rats have been studied by intravenous administration. The hormone caused an increase in the time of survival compared to the group of rats without treatment (102 +/- 4.5 vs. 25 +/- 4.5 min, p < 0.01, vehicle; 102 +/- 4.5 vs. 25 +/- 2 min, p < 0.01, saline solution) and an increase in the percentage of the surviving animals (5/7 after 120 min vs. 0/7, p < 0.05). The animals treated showed an increase in mean arterial pressure that was not present in the control group. Through their data, the authors suggest the vasopressor effect of erythropoietin. Furthermore, from other studies done before, they hypothesize that the vasoactive ability of the hormone is endothelin mediated.
Assuntos
Pressão Sanguínea/efeitos dos fármacos , Eritropoetina/farmacologia , Choque Hemorrágico/tratamento farmacológico , Animais , Eritropoetina/administração & dosagem , Humanos , Injeções Intravenosas , Masculino , Ratos , Ratos Sprague-Dawley , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/farmacologia , Choque Hemorrágico/fisiopatologia , Fatores de Tempo , Resistência Vascular/efeitos dos fármacosRESUMO
Intracerebroventricular (i.c.v.) injection of magnesium sulphate (MgSO4:2.5, 5 and 10 mumol in 5 microliters) decreased blood pressure and heart rate in both anesthetized normotensive (WKY) and hypertensive rats (SHR). The effects were greater in WKY than in SHR. Moreover, a pretreatment with hexamethonium (2 mg/kg, i.v.) significantly blunted the hypotensive and bradycardic effects induced by i.c.v. injection of 10 mumol of MgSO4 in both WKY and SHR. Our data suggest that MgSO4 produces hypotensive and bradycardic effects when injected i.c.v. in both WKY and SHR.
Assuntos
Pressão Sanguínea/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Hipertensão/fisiopatologia , Sulfato de Magnésio/farmacologia , Anestesia , Animais , Injeções Intraventriculares , Sulfato de Magnésio/administração & dosagem , Masculino , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKYRESUMO
Debrisoquine and S-mephenytoin hydroxylation phenotyping tests were performed in 9 patients before and during treatment with diazepam at a daily dose of 10 or 15 mg. There was no change in either the debrisoquine/4-hydroxydebrisoquine ratio or the ratio of S/R mephenytoin in urine. The hydroxylation of these two test drugs is apparently not inhibited by administration of therapeutic doses of diazepam.
Assuntos
Debrisoquina/metabolismo , Diazepam/farmacologia , Hidantoínas/metabolismo , Isoquinolinas/metabolismo , Mefenitoína/metabolismo , Adulto , Debrisoquina/análogos & derivados , Interações Medicamentosas , Humanos , Hidroxilação , Masculino , Pessoa de Meia-Idade , FenótipoRESUMO
The authors evaluated the clinical effectiveness and tolerability of doxofylline, a new methyl-xanthinic derivative with peculiar pharmacodynamic properties. 13 patients affected with chronic obstructive lung disease (mean age +/- 54 years) were studied. Doxofylline (200 mg) and theophylline (240 mg) were randomly administered by intravenous route in 60'. Arterial haemogasanalysis, FEV1 and ECG data were obtained after the infusion. Doxofylline proved to possess an equal therapeutic efficacy in comparison to theophylline, with a better clinical tolerability. In conclusion, doxofylline is a new and effective drug for the treatment of bronchostructive disorders.